Wait...

Online India Export Import Data Search

Complete Training Video : Click Here

Domestic drugmakers face squeeze in US healthcare market.


Date: 18-03-2017
Subject: Domestic drugmakers face squeeze in US healthcare market
MUMBAI: India's small and medium-sized generic drugmakers say the threat of tougher rules and higher barriers for outsiders in the U.S. healthcare market will force many to find a niche or focus their expansion efforts on other countries. 

India supplies nearly a third of medicines sold in the United States, the world's largest healthcare market. Cut-price generics sold by India's small- and medium-sized drugmakers have been critical in bringing down prices there. 

A more protectionist stance by President Donald Trump, with the prospect of import tariffs and the U.S. boosting local drug manufacturing, mean the operating environment for smaller generic players will get worse, executives at Indian companies said. 

"If the challenges keep increasing, competition will reduce, and this could actually increase prices there," said D.G. Shah, secretary general of the Indian Pharmaceutical Association, which represents 20 large Indian drugmakers. 

J. Jayaseelan, who owns Nuray Chemicals, a maker of drug ingredients, said many Indian firms are reconsidering, or putting on hold, U.S. expansion plans. 

Ajanta PharmaBSE 1.80 % (AJPH.NS) is one such firm. The mid-sized generics drug maker said it had no plans to scale up its U.S. business and would invest more in Asia and Africa instead. 

"It's not a major market for us right now ... you've got to look at the risk-reward ratio," said Rajeev Agarwal, general manager of finance at Ajanta. 

The risks comes as U.S. revenue growth for these firms is falling. U.S. revenues for Indian drugmakers rose 15 percent in 2016, half the average annual growth rate of 33 percent between 2011 and 2015, ratings agency ICRABSE 0.24 % said. It expects the growth rate to fall further this year. 

Consolidation among U.S. drugs distributors and a federal investigation into drug pricing have also reduced the pricing power of drugsmakers. 

The U.S. drugs regulator, the Food and Drug Administration, has also banned dozens of Indian drug factories from supplying the U.S. market following inspections that found inadequate quality-control practices. Companies have invested significant sums to raise their quality standards. 

Firms that want to focus on the United States will have to increase investment in higher-margin niche therapies, or products requiring specialized manufacturing, said Mitanshu Shah, senior vice president of finance at Alembic PharmaceuticalsBSE 0.17 % (ALEM.NS). 

"Smaller companies with a few regular products and no long-term vision for the United States won't last," Shah said. 

Even with a vision, the U.S. market is just getting tougher for companies to operate in, said Vijay Ramanavarapu, the head of the U.S. business of drugmaker Granules India BSE -0.31 % (GRAN.NS). 

"You have to fight twice as hard today," Ramanavarapu said. "It will be harder for new entrants to enter the U.S. market unless they are able to find niche areas."

Source: economictimes.indiatimes.com

DO YOU NEED HELP?

Get Sample Now

Which service(s) are you interested in?
 Export Data
 Import Data
 Both
 Buyers
 Suppliers
 Both
OR
 Exim Help
+


What is New?

Date: 18-05-2017
Notification No.49/2017 - Customs (N.T.)
Rate of exchange of conversion of the foreign currency with effect from 19th May, 2017

Date: 16-05-2017
Notification No.48/2017 - Customs (N.T.)
Seeks to amend the Customs notification No. 84/2007-Customs (N.T.) dated 17th August, 2007 to give effect to the amendments to Rules of Origin of India-Chile PTA

Date: 16-05-2017
Notification No. 20/2017-Customs
Seeks to amend notification no. 12/2012-customs dated 17.03.2012 extending the time period for furnishing the final Mega power project certificate from 60 months to 120 months and extending the period of validity of security in the form of Fixed Deposit Receipt or Bank Guarantee from 66 months to 126 months, in case of provisional mega power projects

Date: 16-05-2017
Notification No. 19/2017-Customs
seeks to amend notification No. 101/2007 – Customs dated 11th September 2007 so as to notify the expanded schedule of tariff preferences under the India-Chile Preferential Trade Agreement (PTA).

Date: 16-05-2017
Notification No. 23/2017-Customs (ADD)
Seeks to levy definitive anti-dumping duty, on imports of Aluminium Foil originating in or exported from China PR

Date: 16-05-2017
Notification No. 22/2017-Customs (ADD)
Seeks to amend notification No. 23/2016-Customs (ADD) dated 06.06.2016 vide which anti-dumping duty was imposed on imports of Polytetraflouroethylene (PTFE) originating in or exported from Russia so as to revise of the amount of anti-dumping duty applicable from US$ 739.77/MT to US$ 874.56/MT

Date: 16-05-2017
Notification No. 21/2017-Customs (ADD)
Seeks to levy definitive anti-dumping duty on import of Amoxycillin originating in or exported from China PR for a period of five years (unless revoked, superseded or amended earlier) in pursuance of final findings of the Directorate General of Anti-Dumping and Allied Duties.

Date: 16-05-2017
Central Excise Notification No. 08/2017
seeks to amend notification no. 12/2012-Central Excise dated 17.03.2012 extending the time period for furnishing the final Mega power project certificate from 60 months to 120 months and extending the period of validity of security in the form of Fixed Deposit Receipt or Bank Guarantee from 66 months to 126 months, in case of provisional mega power projects.

Date: 15-05-2017
Notification No.47/2017 - Customs (N.T.)
Tariff Notification in respect of Fixation of Tariff Value of Edible Oils, Brass Scrap, Poppy Seeds, Areca Nut, Gold and Sliver

Date: 12-05-2017
Notification No. 20/2017-Customs (ADD)
Seeks to impose definitive anti-dumping duty on imports of Aluminium Radiators, Aluminium Radiator Sub-Assemblies and Aluminium Radiator Core, originating in, or exported from, China PR